➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Medtronic
Harvard Business School
Express Scripts
Colorcon

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

CHILDREN'S ZYRTEC HIVES RELIEF Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Children's Zyrtec Hives Relief, and when can generic versions of Children's Zyrtec Hives Relief launch?

Children's Zyrtec Hives Relief is a drug marketed by J And J Consumer Inc and is included in two NDAs.

The generic ingredient in CHILDREN'S ZYRTEC HIVES RELIEF is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and thirty-three suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Children's Zyrtec Hives Relief

A generic version of CHILDREN'S ZYRTEC HIVES RELIEF was approved as cetirizine hydrochloride by TEVA PHARMS on May 27th, 2008.

  Get Started for $10

Drug patent expirations by year for CHILDREN'S ZYRTEC HIVES RELIEF
Recent Clinical Trials for CHILDREN'S ZYRTEC HIVES RELIEF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme Corp.Phase 4
Merck Sharp & Dohme Corp.Phase 3
Johnson & Johnson Consumer and Personal Products WorldwidePhase 4

See all CHILDREN'S ZYRTEC HIVES RELIEF clinical trials

Paragraph IV (Patent) Challenges for CHILDREN'S ZYRTEC HIVES RELIEF
Tradename Dosage Ingredient NDA Submissiondate
CHILDREN'S ZYRTEC HIVES RELIEF TABLET, CHEWABLE;ORAL cetirizine hydrochloride 021621 2005-03-25
CHILDREN'S ZYRTEC ALLERGY TABLET, CHEWABLE;ORAL cetirizine hydrochloride 021621 2005-03-25

US Patents and Regulatory Information for CHILDREN'S ZYRTEC HIVES RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc CHILDREN'S ZYRTEC HIVES RELIEF cetirizine hydrochloride SYRUP;ORAL 022155-001 Nov 16, 2007 OTC Yes Yes   Get Started for $10   Get Started for $10   Get Started for $10
J And J Consumer Inc CHILDREN'S ZYRTEC HIVES RELIEF cetirizine hydrochloride TABLET, CHEWABLE;ORAL 021621-005 Nov 16, 2007 DISCN Yes No   Get Started for $10   Get Started for $10   Get Started for $10
J And J Consumer Inc CHILDREN'S ZYRTEC HIVES RELIEF cetirizine hydrochloride TABLET, CHEWABLE;ORAL 021621-006 Nov 16, 2007 DISCN Yes No   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CHILDREN'S ZYRTEC HIVES RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
J And J Consumer Inc CHILDREN'S ZYRTEC HIVES RELIEF cetirizine hydrochloride TABLET, CHEWABLE;ORAL 021621-005 Nov 16, 2007   Get Started for $10   Get Started for $10
J And J Consumer Inc CHILDREN'S ZYRTEC HIVES RELIEF cetirizine hydrochloride TABLET, CHEWABLE;ORAL 021621-006 Nov 16, 2007   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for CHILDREN'S ZYRTEC HIVES RELIEF

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0058146 SPC/GB01/052 United Kingdom   Get Started for $10 SPC/GB01/052:, EXPIRES: 20070205
0663828 C300085 Netherlands   Get Started for $10 PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146 2001C/045 Belgium   Get Started for $10 PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
McKesson
Harvard Business School
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.